Anti-pcsk9 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. SLEEMAN, Joel H. MARTIN, Tammy T. HUANG, Douglas MACDONLAD
Life of this patent
Estimating the term…
Abstract
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Claims15
A nucleic acid molecule encoding a heavy chain variable region (HCVR) of an anti-human PCSK9 antibody or antigen-binding fragment thereof, wherein the HCVR comprises a heavy chain complementarity determining region (HCDR)1 comprising SEQ ID NO:76, an HCDR2 comprising SEQ ID NO:78, and an HCDR3 comprising SEQ ID NO:80.
A nucleic acid molecule encoding a light chain variable region (LCVR) of an anti-human PCSK9 antibody or antigen-binding fragment thereof, wherein the LCVR comprises a light chain complementarity determining region (LCDR)1 comprising SEQ ID NO:84, an LCDR2 comprising SEQ ID NO:86, and an LCDR3 comprising SEQ ID NO:88.
3-6. (canceled)
A method of producing an anti-human PCSK9 antibody or antigen-binding fragment thereof, the method comprising:
- culturing a host cell under conditions permitting production of the antibody or antigen-binding fragment thereof, wherein the host cell comprises:
- (i) a first recombinant expression vector comprising a nucleic acid molecule encoding an HCVR of the anti-human PCSK9 antibody, wherein the HCVR comprises an HCDR1 comprising SEQ ID NO:76, an HCDR2 comprising SEQ ID NO:78, and an HCDR3 comprising SEQ ID NO:80;
- and (ii) a second recombinant expression vector comprising a nucleic acid molecule encoding a LCVR of the anti-human PCSK9 antibody, wherein the LCVR comprises an LCDR1 comprising SEQ ID NO:84, an LCDR2 comprising SEQ ID NO:86, and an LCDR3 comprising SEQ ID NO:88;
- and
- recovering the antibody or antigen-binding fragment produced.
Dependencies are inferred from the claim text.